Go Deep
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,730 | -4.4 | 2.16 | 0.00 | 1,532.31 |
| Oct 2026 | 20,707 | -4.5 | 2.18 | 0.00 | 1,538.15 |
| Oct 2026 | 20,585 | -4.6 | 2.26 | 0.00 | 1,594.40 |
| Oct 2026 | 20,612 | -4.6 | 2.24 | 0.00 | 1,577.95 |
| Oct 2026 | 20,347 | -5.0 | 2.41 | 0.00 | 1,701.01 |
| Oct 2026 | 20,158 | -5.2 | 2.53 | 0.00 | 1,787.29 |
| Oct 2026 | 20,102 | -5.3 | 2.57 | 0.00 | 1,808.41 |
| Oct 2026 | 20,086 | -5.3 | 2.58 | 0.00 | 1,812.30 |
ArriVent BioPharma, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -49,893,000.0 | -43,320,000.0 | -35,544,000.0 | -34,978,000.0 |
| EPS | -1.1 | -1.0 | — | -0.8 |
ArriVent BioPharma, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -166,308,000.0 | -80,488,000.0 | -69,333,000.0 | -36,906,000.0 |
| EPS | -4.3 | -2.6 | -2.2 | -1.2 |
ArriVent BioPharma, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 333,169,000.0 | 274,942,000.0 | 163,098,000.0 | 182,833,000.0 | — |
| Total Liabilities | 25,945,000.0 | 17,288,000.0 | 316,291,000.0 | 267,942,000.0 | — |
| Total Equity | 307,224,000.0 | 257,654,000.0 | -153,193,000.0 | -85,109,000.0 | — |
Owes vs Owns
ArriVent BioPharma, Inc. owed $0.07 for every $1 it owned in Jun 2026, down from $1.47 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.07× | 0.08× | 0.06× | 1.94× | 1.47× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
ArriVent BioPharma, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 93.9%Other assets 6.1%
How it's funded — Dec 2025
Payables 1.8%Other liabilities 6.0%Shareholders' equity 92.2%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 312.8 | 218.9 | 150.4 | 163.4 |
| Receivables | 0.1 | 0.5 | 0.8 | 0.5 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.2 | 0.3 | 0.1 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 47.7 | 0.0 | 0.0 |
| Other assets | 20.3 | 7.7 | 11.7 | 18.8 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.2 | 0.1 | 0.1 |
| Long-term debt | 0.0 | 0.0 | 0.2 | 0.0 |
| Payables | 5.9 | 3.8 | 4.5 | 3.1 |
| Other liabilities | 20.0 | 13.3 | 311.4 | 264.7 |
| Shareholders' equity | 307.2 | 257.7 | -153.2 | -85.1 |
| Net tangible assets | 307.2 | 257.7 | -153.2 | -85.1 |
ArriVent BioPharma, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | -160,588,000.0 | -70,212,000.0 | -55,842,000.0 | -43,631,000.0 |
| Investing Activities | -71,228,000.0 | -192,465,000.0 | 0.0 | 0.0 |
| Financing Activities | 203,063,000.0 | 186,581,000.0 | 42,859,000.0 | 169,723,000.0 |